CSIMarket
 
Pmv Pharmaceuticals Inc   (PMVP)
Other Ticker:  
 
 
Price: $1.8750 $0.03 1.351%
Day's High: $2.11 Week Perf: 4.17 %
Day's Low: $ 1.80 30 Day Perf: 6.53 %
Volume (M): 839 52 Wk High: $ 9.72
Volume (M$): $ 1,574 52 Wk Avg: $4.45
Open: $1.80 52 Wk Low: $1.18



 Market Capitalization (Millions $) 92
 Shares Outstanding (Millions) 49
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 3

Pmv Pharmaceuticals Inc
PMV Pharmaceuticals Inc is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs that target p53, a tumor-suppressor protein that plays a key role in preventing the development and progression of cancer. The company was founded in 2013 by Dr. Arnold Levine and is headquartered in Cranbury, New Jersey.

PMV Pharma's lead product candidate, PMV-01, is a small molecule that restores the activity of mutant p53 proteins, which are found in over 50% of all human cancers. PMV Pharma is developing PMV-01 for the treatment of a variety of cancers, including ovarian, colorectal, breast, and lung cancers. PMV-01 has completed Phase 1 clinical trials and is currently in Phase 2 clinical trials.

The company has also developed a proprietary drug discovery platform called R-x Discovery, which uses high throughput screening and medicinal chemistry to identify and optimize small molecule drug candidates that target p5 Through this platform, PMV Pharma has identified several preclinical drug candidates that it plans to advance into clinical trials.

PMV Pharma has raised over $300 million in funding to date from a variety of sources, including venture capital firms, strategic investors, and public markets. The company went public in June 2020 and is traded on the NASDAQ under the ticker symbol PMVP.

The company is led by a team of experienced biotech executives, including CEO and President David Mack, who has over 20 years of experience in the pharmaceutical industry. PMV Pharma's board of directors includes several distinguished scientists and business leaders, including Dr. Arnold Levine, the company's founder and a professor of oncology at the Institute for Advanced Study in Princeton, New Jersey.

Overall, PMV Pharmaceuticals Inc is a leading biotech company that is focused on developing innovative cancer therapies that target p53, a key tumor-suppressor protein. With its proprietary drug discovery platform and experienced leadership team, PMV Pharma is well-positioned to make significant contributions to the field of cancer research and treatment in the years to come.


   Company Address: One Research Way Princeton 8540 NJ
   Company Phone Number: 642-6670   Stock Exchange / Ticker: NASDAQ PMVP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

PMV Pharmaceuticals Reinforces Leadership Team: Spearheading Transformative Cancer Therapies

Published Fri, Jan 5 2024 9:01 PM UTC

PMV Pharmaceuticals: Bolstering Leadership for Late-Stage Development Success
PMV Pharmaceuticals, a pioneering precision oncology company specializing in the development of small molecule therapies targeting p53, has recently made strategic appointments to its leadership team. These key additions come as the company advances into late-stage development, solidifying its ...

Pmv Pharmaceuticals Inc

Pmv Pharmaceuticals Inc: Powering Through Challenges to Rebound Stronger in Q3 2023



The Major Pharmaceutical Preparations industry advisors have recently assessed Pmv Pharmaceuticals Inc's third-quarter financial results for 2023. The company reported an operating loss of $-19.628 million, while no revenue figures have been released yet. These disappointing figures continue to raise concerns about the company's financial stability. This article delves into the recent financial performance, examines the historical context, and highlights the concerning trends that should worry investors.
Lack of Revenue and Ever-Increasing Losses
Pmv Pharmaceuticals Inc's Q3 financial results for 2023 indicate that the company has not generated any revenue. This absence of revenue is especially concerning since it represents a continued trend from the previous reporting period. The lack of revenue further underscores the uncertainty surrounding the company's ability to generate profits in the near future.

Pmv Pharmaceuticals Inc

PMVP Reports Operating Deficit of $-20.122 Million in Q2 2023, Highlights Need for Further Financial Insights


Introduction
The Major Pharmaceutical Preparations industry has experienced mixed results in the second quarter of 2023. Pmv Pharmaceuticals Inc, one of the industry contributors, recently reported an operating deficit of $-20.122 million for the period. This article aims to analyze this performance and compare it to the previous year's results.
Q2 2023 Performance
Pmv Pharmaceuticals Inc has reported a significant operating deficit of $-20.122 million for the second quarter of 2023. However, it is worth noting that the company has not yet cited any top-line figures for this period. Therefore, it will be crucial to wait for further financial reporting to gain a complete understanding of the company's performance.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com